Blood Glucose Testing and Diabetes Management

Description:
There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe.

Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes, particularly Type 2 diabetes, among adults across the world. As such, the global market for blood glucose testing products is undergoing a significant transition driven by the advent of new analytical technologies and developments in diabetes treatment. Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, certain segments of the market, such as home testing devices for diabetes management, will exhibit strong growth.

What's more, non-invasive testing now represents a major new area for the application of IVD testing. Additionally, direct access testing - or over-the-counter testing, which allows consumers to order tests themselves without visiting a doctor - has emerged as a strong force in the blood glucose testing segment. The purpose of this report is to describe the specific market segments for blood glucose testing and diabetes management. This study reviews all of the generally-accepted clinical analytical methods that are currently in use today for measuring serum or plasma or whole-blood glucose concentrations. Moreover, it examines clinical measurement devices, reagents and supplies as utilized in hospitals, clinics, doctor's offices and at-home care locations.

The report has made a survey of selected companies marketing, manufacturing or developing various blood glucose testing and diabetes management supplies throughout the world. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market share data are also included.

Contents:
1. Overview
   1.1 Statement of Report
   1.2 About this Report
   1.3 Scope of the Report
   1.4 Methodology
   1.5 Executive Summary

2. Diabetes
   2.1 Demographics of Diabetes
   2.1.1 Worldwide Diabetes Incidence
   2.1.2 Diabetes in the U.S.
   2.2 Understanding the Metabolic Conditions Underlying and Associated with Diabetes
   2.2.1 Pre-Diabetes Syndrome
   2.2.2 Metabolic Syndrome
   2.2.3 Progression of Diabetes
   2.2.4 Diabetes and Inflammation
   2.2.5 Risk Factors and Diabetes
   2.2.5.1 Obesity
   2.2.5.2 Stress-Induced Hyperglycemia
   2.2.6 Complications and Co-Morbidities in Diabetes
   2.2.6.1 Preventing Complications and Co-Morbidities in Diabetes
   2.2.6.2 Cardiovascular Disease Facts
   2.3 Economics of Diabetes
   2.3.1 Worldwide Costs of Diabetes
   2.3.2 Costs of Diabetes in the U.S.

3. Market Analysis: Size, Growth, Share and Competitors
   3.1 Worldwide Glucose Testing Market
3.1.1 Global Blood Glucose Self-Testing Market
3.1.2 Worldwide Professional Blood Glucose Testing Market
3.1.3 Continuous Glucose Monitoring Markets
3.2 U.S. Market
3.2.1 U.S. Over-the-Counter (OTC) Self-Testing Glucose Market
3.2.2 U.S. Professional Glucose Testing Market
3.3 European Market
3.4 Asian Market
3.4.1 Japanese Market
3.4.2 Chinese Market
3.4.3 Indian Market
3.4.4 Korean Market
3.4.5 Southeast Asian Market
3.4.6 ROW Markets
3.5 Competitive Situation
3.5.1 Key Players in the Self-testing Market
3.5.2 Analyses of the Self-testing Market Conditions, Competition and Product Mix
3.5.3 Analyses of the Professional Blood Glucose Monitoring Market
3.6 Market Drivers and Restraints
3.6.1 Market Drivers
3.6.2 Market Restraints
3.7 Market and Product Trends
3.7.1 Market Trends
3.7.2 Technology Trends
3.8 Strategic Recommendations
3.9 Competitive Strategies
3.10 New Opportunities in the Professional Blood Glucose Meter Market
3.11 Adjacent Markets

4. Glucose Diagnostic and Monitoring Recommendations
4.1 Diagnosis of Diabetes Mellitus
4.2 Tight Glucose Control in Treating Diabetes
4.2.1 Tight Glucose Control Lowers Cardiovascular Complications
4.3 Recommendations for Glucose Control in Diabetic Patients
4.3.1 New Plasma Blood Sugar and HbA1c Target Recommendation for Children with Type 1 Diabetes
4.3.2 Recommended Frequency of Blood Glucose Testing
4.3.3 Using Blood Glucose Data to Monitor and Modify Patient Therapy
4.3.4 Testing in Individuals with Type 2 Diabetes
4.3.5 Continuous Glucose Monitoring (CGM)
4.3.6 A1c Testing Recommendations
4.3.7 Blood Glucose Testing for All Hospitalized Patients According to Guidelines by The Endocrine Society
4.4 Hypoglycemia and Treatment

5. Glucose Testing Technology Platforms and Consumable Products
5.1 Types of Glucose Determination Technologies
5.2 Enzymatic Reactions Used to Determine Glucose Concentrations
5.2.1 Glucose Oxidase (GOX)
5.2.2 Glucose Dehydrogenase (GDH)
5.2.2.1 GDH-NAD (Glucose Dehydrogenase-Nicotinamide Adenine Dinucleotide)
5.2.2.2 GDH-FAD (Glucose Dehydrogenase-Flavin Adenine Dinucleotide)
5.2.2.3 GDH-PQQ (Glucose Dehydrogenase-Pyrroloquinoline Quinone)
5.2.3 Glucose Hexokinase
5.3 Development of Blood Glucose Monitors: A Historical Evaluation
5.3.1 First Generation Blood Glucose Biosensors
5.3.2 Second Generation Blood Glucose Biosensors
5.3.3 Third Generation Blood Glucose Biosensor
5.4 Accuracy and Precision in Glucose Meters
5.4.1 Clinical and Laboratory Standards Institute (CLSI) POCT12-A3
5.4.2 International Organization for Standardization (ISO) 15197:2013
5.4.3 FDA Guidelines for Blood Glucose Testing Systems
5.4.4 Determining Clinical Accuracy Using the Error Grid Analysis (EGA)
5.4.5 Quality Control Criteria
5.4.6 Potential Variables Affecting Glucose Concentrations
5.5 Key Issues for Glucose Testing Devices
5.5.1 Important Elements for Glucose Testing
5.5.2 Key Features to Aid Specific Patient Populations
5.6 Limitations of Existing Glucose Testing
5.6.1 Common User Errors in Glucose Self-Testing
5.6.2 Interfering Substances and Conditions
5.6.2.1 Environmental
5.6.2.2 Physiologic
5.6.2.3 Operational
5.6.2.4 Manufacturing Variations
5.6.2.5 Drugs/Medications
5.6.3 Errors Associated with GDH-PQQ Technology
5.6.4 Optimizing of Point-of-Care (POC) Blood Glucose Testing
5.7 Potential Areas of Improvement in Blood Glucose Meter Performance
5.7.1 Off-Label/Modified Use of Waived Blood Glucose Monitoring Systems
5.8 Blood Glucose Reagent Test Strips
5.9 Comparison of Hand-Held Blood Glucose Meters with Clinical Laboratory Glucose Measurements
5.10 Continuous Glucose Monitoring Technology
5.10.1 Advantages of Continuous Readings
5.10.2 FDA Approval of CGM
5.10.3 CGM Functions to Consider
5.10.4 New Technologies for CGM
5.11 Summary of Technologies Being Explored for Non-invasive Glucose Monitoring
5.11.1 GlucoTrack
5.11.2 Non-invasive Glucose Monitoring Technologies in Development
5.11.3 Goals of Non-Invasive Testing
5.11.4 Non-Invasive Diabetes Screening Test
5.12 A1c Monitoring Technology
5.12.1 PTS Diagnostics' (Chek Diagnostics') A1c Home Test
5.13 Fructosamine Test
5.14 Related Reagents and Equipment
5.14.1 Lancets
5.14.1.1 Types of Lancing Devices
5.14.1.2 Market Size
5.14.2 Control Solutions and Calibrators
5.14.3 Sharps Devices
5.14.4 Needle Destruction Devices
5.14.5 Urine Strips
5.14.6 Ketone Testing
5.14.7 Long-term Glucose Sensing Bio-implants

6. Glucose Testing Devices on the Market
6.1 Hand-Held Blood Glucose Meters and Strips for Self-testing
6.1.1 LifeScan
6.1.2 Roche Diagnostics Corporation
6.1.3 Bayer
6.1.4 Abbott (MediSense)
6.1.5 AgaMatrix, Inc.
6.1.6 ARKRAY, Inc.
6.1.7 Bionime Corporation
6.1.8 BioSense Medical Devices
6.1.9 CVS/pharmacy
6.1.10 Diabetic Supply of Suncoast
6.1.11 Entra Health Systems
6.1.12 Fifty50 Pharmacy
6.1.13 Fora Care
6.1.14 Genesis Health Technologies
6.1.15 GlucoCare
6.1.16 iHealth
6.1.17 Infopia
6.1.18 Livongo Health
6.1.19 Nipro Diagnostics, Inc.
6.1.20 Nova Biomedical
6.1.21 Oak Tree International Holdings, Inc.
6.1.22 Omnis Health
6.1.23 Phylosis
6.1.24 Prodigy Diabetes Care, LLC (an affiliate of Diagnostic Devices, Inc.)
6.1.25 Sanofi
6.1.26 Target
6.1.27 Telcare
6.1.28 Tyson Biomedical
6.1.29 US Diagnostics
6.1.30 Walgreens
6.1.31 Walmart
6.1.32 77 Elektronika Kft.
6.1.33 A. Menarini Diagnostics
6.1.34 All Medicus
6.1.35 i-SENS
6.1.36 Apex Biotechnology Corp.
6.1.37 Glucoplus, Inc.
6.1.38 Polymer Technology Systems
6.1.39 Smiths Medical MD, Inc.
6.1.40 TaiDoc Technology Corp.
6.1.41 IN4 Technology Corporation
6.1.42 ACON Laboratories
6.1.43 Pepex Biomedical
6.1.44 HMD BioMedical
6.1.45 BTNX
6.1.46 Decision Diagnostics Corporation and Pharma Tech Solutions
6.2 Point of Care Blood Glucose Meters for Professional Use
6.2.1 Abbott
6.2.1.1 Precision Xceed ProÒ Blood Glucose and Beta-Ketone Monitoring System
6.2.1.2 i-STATÒ System
6.2.2 Alere
6.2.2.1 epoc® Blood Analysis System
6.2.2.2 Alere Cholestech LDX System
6.2.3 Apex Biotechnology
6.2.4 ARKRAY
6.2.4.1 AssureÔ Platinum and Assure Prism Multi
6.2.5 EKF Diagnostics
6.2.5.1 Biosen Series of Glucose and Lactate Analyzers
6.2.6 Fora Care
6.2.6.1 VSM100 Pro Vital Sign Monitor
6.2.7 HemoCue (part of Radiometer)
6.2.7.1 HemoCueÒ Glucose 201+, Glucose 201 RT, Glucose 201 DM, and Glucose DM RT Systems
6.2.8 HMD BioMedical
6.2.8.1 NS101
6.2.9 Infopia
6.2.9.1 Lipid Pro
6.2.10 Jant Pharmacal
6.2.10.1 LipidPlus® Lipid Profile and Glucose Measuring System
6.2.11 Medtronic
6.2.11.1 iPro™ Continuous Glucose Monitor
6.2.12 Nova Biomedical
6.2.12.1 StatStripÒ Hospital Glucose Monitoring System
6.2.13 Polymer Technology Systems
6.2.13.1 CardioChek® PA Point-of-Care Device
6.2.14 Roche
6.2.14.1 Accu-ChekÒ Inform II System
6.2.14.2 AccutrendÒ Plus System
6.2.15 Techno Medica Co., Ltd
6.2.15.1 GASTAT-mini
6.2.16 LifeScan
6.3 Clinical Blood Chemistry Analyzers
6.3.1 Abaxis, Inc.
6.3.1.1 Piccolo® Xpress Blood Chemistry Analyzers
6.3.2 Abbott
6.3.2.1 ARCHITECT
6.3.3 Alere
6.3.3.1 Cholestech LDX® System
6.3.4 AMS
6.3.4.1 SAT 600
6.3.4.2 SAT 450
6.3.4.3 LIASYS
6.3.4.4 ELLIPSE
6.3.4.5 NEPHYS
6.3.4.6 VEGASYS
6.3.5 ARKRAY, Inc.
6.3.5.1 SPOTCHEM™ EZ
6.3.5.2 SPOTCHEM D-02 (SD-4810) & SPOTCHEM D-03 (SD-4820)
6.3.6 Beckman Coulter
6.3.6.1 AU chemistry systems
6.3.6.2 UniCel® DxC chemistry systems
6.3.7 DiaSys
6.3.7.1 InnovaStar®
6.3.7.2 SensoStar GL30 touch and SensoStar GLHsix
6.3.7.3 respons® 910 and 920
6.3.7.4 BioMajesty® JCA-BM6010/C
6.3.8 Diatron
6.3.8.1 Pictus 500
6.3.8.2 Pictus 700
6.3.8.3 Pictus 400
6.3.8.4 Pictus 200
6.3.8.5 Pictus B
6.3.9 Instrumentation Laboratory
6.3.9.1 IL GEM Premier 4000, 3500 and 3000
6.3.10 LifeHealth (formerly International Techidyne Corporation)
6.3.10.1 IRMA TruPoint®
6.3.11 Nova Biomedical
6.3.11.1 Nova Electrolyte/Chemistry Analyzers
6.3.11.2 Stat Profile® Critical Care Xpress
6.3.11.3 Stat Profile® pHOx® Plus
6.3.11.4 Stat Profile® pHOx® Ultra
6.3.12 Radiometer™
6.3.12.1 ABL™80 FLEX
6.3.12.2 ABL™90 FLEX
6.3.12.3 ABL™800 FLEX
6.3.13 Randox Laboratories
6.3.13.1 RX Series of clinical chemistry analyzers
6.3.14 Roche
6.3.14.1 cobas® 4000, cobas® 6000, and cobas® 8000 modular Analyzer Series
6.3.14.2 cobas® c 111 Analyzer
6.3.14.3 cobas® b 221 System
6.3.14.4 Reflotron® Systems
6.3.15 Siemens Healthcare Diagnostics
6.3.15.1 Point-of-care Blood Gas Analyzers
6.3.15.2 Central (Core) Laboratory Clinical Chemistry Systems
6.3.16 Span Diagnostics
6.3.16.2 BT 1500
6.3.17 Stanbio Laboratory
6.3.17.1 Excel Semi-Automated Clinical Chemistry Analyzer
6.3.17.2 Sirrus® Clinical Chemistry Analyzer
6.3.18 Thermo Fisher Scientific
6.3.19 Konelab™ 20XT Clinical Chemistry Analyzer
6.3.19.4 Konelab™ PRIME 60 Clinical Chemistry Analyzer
6.3.19.5 MGC 240 Benchtop Analyzer
6.3.20 Tokyo Boeki Medisys
6.3.20.1 BiOLis family of analyzers
6.3.21 YSI Life Sciences
6.3.21.1 YSI 2300 STAT Plus™ Glucose & Lactate Analyzer
6.4 Continuous Glucose Patient Monitoring Systems
6.4.1 Medtronic’s Continuous Glucose Monitoring Systems (CGMS)
6.4.1.1 MiniMed Paradigm REAL-Time Revel System
6.4.1.2 Guardian REAL-Time
6.4.1.3 MiniMed 530G with Enlite
6.4.1.4 iPro®2 Professional CGM
6.4.2 Dexcom, Inc.’s Continuous Glucose Monitoring System
6.4.2.1 G4 Platinum Continuous Glucose Monitoring System
6.4.2.2 Dexcom G4 Platinum Continuous Glucose Monitoring System with Share
6.4.2.3 Dexcom G5 Mobile Continuous Glucose Monitoring System
6.4.3 Animas Vibe System
6.4.4 Abbott’s Continuous Glucose Monitor System
6.4.4.1 FreeStyle Libre
6.4.4.2 FreeStyle Navigator (discontinued)
6.4.5 GlucoDay® S Continuous Glucose Monitor
6.4.6 Minimally-Invasive Continuous Glucose Monitors in Development
6.4.6.1 GlySens Inc.
6.4.6.2 Senseonics (formerly Sensors for Medicine and Science)
6.4.6.3 Ultradian
6.5 Non-Invasive Glucose Patient Monitoring Systems
6.5.1 Cygnus GlucoWatch Biographer
6.5.2 AiMedics
6.5.3 Echo Therapeutics
6.5.4 EyeSense GmbH
6.5.5 Freedom Meditech
6.5.6 Google and Novartis
6.5.7 Integrity Applications Ltd.
6.5.8 Lein Applied Diagnostics
6.5.9 LighTouch Medical
6.5.10 Miraculins, Inc.
6.5.11 Xhale Inc.
6.6 A1c Testing
6.7 New Product Launches
6.7.1 OneTouch® Verio®Sync Blood Glucose Monitoring System
6.7.2 Medtronic’s MiniMed 530G with Enlite Sensor Technology
6.7.3 Contour Next Link Meter Approved for Use with Medtronic’s New MiniMed 530G with Enlite Insulin Pump System
6.7.4 Abbott Receives CE Mark for FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System
6.7.5 Abbott Receives FDA Clearance for FreeStyle Precision Pro Blood Glucose and β–Ketone Monitoring System
6.7.6 LabStyle Innovations’ Dario Diabetes Management System
6.7.7 BlueStar by WellDoc
6.7.8 FDA Approves Bayer’s Contour Next EZ
6.7.9 Glooko Received its Second 510(k) Clearance for Glucose Monitoring Logbook App
6.7.10 Sanofi-Aventis’s IBGStar
6.7.11 iHealth Glucose Meter Device
6.7.12 MyGlucoHealth® Diabetes
6.7.13 Enlite™ Sensor
6.7.14 Medtronic Gains Approval of First Artificial Pancreas Device System, the MiniMed® 530G with Enlite®
6.7.15 Nipro Diagnostics TrueMetrix Air
6.7.16 Animas Vibe System
6.7.17 Abbott’s FreeStyle Libre and FreeStyle Libre Pro
6.7.18 Abbott’s FreeStyle Precision Neo Blood Glucose Monitoring System
6.7.19 Dexcom G4 Platinum Continuous Glucose Monitoring System with Share
6.7.20 Medtronic’s MiniMed Connect
6.7.21 Dexcom G5 Mobile CGM System
6.8 Blood Glucose Meters, CGMs, and Data Management Software in Development
6.8.1 Abbott's Flash Glucose Monitoring System
6.8.2 Google Announces Plan to Create Contact Lens Glucose Sensors
6.8.3 Socrates Health Solutions' Companion Blood Glucose Monitor
6.8.4 Boston University's Bionic Pancreas Project
6.8.5 IGI Stat's Test to Identify Type 1 Diabetes
6.8.6 Medtronic's Next-generation Combination Pump and CGM
6.8.7 Medtronic and IBM's Watson Health to Develop Data Management Solutions
6.9 Recent Industry Activity
6.9.1 Roche Diagnostics Corp. Cutting Jobs in Diabetes Division
6.9.2 AgaMatrix and Sanofi-Aventis Enter Global Diabetes Partnership
6.9.3 LifeScan Inc. Terminates Exclusive Supply Agreement with Medtronic MiniMed
6.9.4 Medtronic and Bayer Healthcare Expand International Alliance
6.9.5 PositiveID Corporation Licenses iglucose Technology to Smart Glucose Meter Corp
6.9.6 BD and JDRF Collaborating on a Device Using a Single Infusion Catheter for Both CGM and Pump
6.9.7 Court Sides with Decision Diagnostics in Patent Infringement Case
6.9.8 Senseonics Partners with Rubin Medical to Commercialize New CGM
6.9.9 Abbott re-entering Continuous Glucose Monitoring Market in Europe with FreeStyle Libre
6.9.10 Medtronic and IBM's Watson Health Partnering to Develop Personalized Diabetes Management Solutions
6.10 M&A Activity
6.10.1 Home Diagnostics, Inc. and Nipro Diabetes Systems, Inc. Merge to Become Nipro Diagnostics, Inc.
6.10.2 Medtronic, Inc. Acquires New Diabetes Technology from PreciSense AS
6.10.3 Geonostics Acquires FlexSite's Consumer Diabetes Tests
6.10.4 Radiometer Medical Acquires Hemocue
6.10.5 Additional M&A
6.10.6 Important Deals in BGM market

7.1 Drivers of Clinical Glucose Testing
7.2 Competition for Professional POC Glucose Testing
7.3 Healthcare Cost Controls
7.4 Changes in Patient Management
7.5 Regionalization of Laboratory Care
7.6 Satellite Facilities
7.7 Professional Point-of-Care Testing
7.8 Factors Affecting OTC Medical Product Distribution
7.9 Drug Stores Critical to the Diabetic Care Category
7.10 Drivers of OTC and Self-Testing Markets
7.10.1 Brand Loyalty
7.11 Cost Elements of Glucose Self-Testing
7.12 Costs of Doing Business in Europe
7.13 Drivers of European Diagnostics Testing
7.14 Cost Containment in Europe
7.15 Blood Glucose Self-Testing Insurance Coverage and Reimbursement
7.15.1 American OTC Testing and Self-Testing Reimbursement
7.15.2 European Reimbursement
7.16 Reimbursement Challenges
7.16.1 New Medicare Part B
7.17 Managed Care
7.18 Government Regulation of Medical Devices
7.18.1 U.S. Regulations
7.18.2 E.U. Regulations
7.18.3 U.K. Regulations
7.19 Clinical Laboratory Improvement Act (CLIA)
7.19.1 Off-Label/Modified Use of Waived Blood Glucose Monitoring Systems
7.20 FDA Labeling Requirements
7.21 Legal Liability for Glucose Meters
7.22 FDA's Artificial Pancreas Guidance Document

8. Technology Trends
8.1 Improving Today's Over-The-Counter (OTC) Blood Glucose Meters
8.2 Biosensor Technology
8.3 Artificial Pancreas
8.4 Telemedicine
8.4.1 Remote Patient Monitoring
8.4.1.1 Infopia Eocene System
8.4.1.2 Health Buddy Systems Monitoring Technologies
8.4.1.3 GlucoCom Glucose Monitoring System
8.4.1.4 Alere’s DayLink® Monitor
8.4.1.5 Alere HomeLink Receives FDA Approval for Over-the-Counter Use
8.4.1.6 iGlucose System
8.5 Non-Traditional Methods for Sample Collection
8.6 Data Management
8.6.1 Medical Device Radiocommunications Service (MedRadio)
8.6.2 Connectivity
8.6.3 Advantages of Connectivity
8.6.4 Connectivity Platforms
8.6.5 DataLink Data Management System
8.6.6 RALS-Plus
8.6.7 FDA Required Software Verification
8.6.8 Information Management Advances
8.6.9 POL Laboratory Data Management
8.6.9.1 Electronic Medical Record Systems and Physician Office Laboratory Data Linking Software
8.6.9.2 Physician Office Laboratory Data Linking Software and Interface to the Laboratory Information System
8.6.9.3 Technical Problems of Connectivity
8.6.9.4 Web-Based Data Interface
8.6.10 HIT Competition

Index Of Figures
Figure 2.1: Worldwide Diabetes Cases, 2014 and 2035
Figure 2.2: Worldwide Prevalence of Diabetes (%) in Adults (20-79 Years)
Figure 2.3: New Cases of Diabetes Diagnosed in the U.S. Adult Population by Age
Figure 2.4: Prevalence of Diabetes by Age in the U.S.
Figure 2.5: Diagnosed Diabetes by Age in the U.S.
Figure 2.6: Percentage of U.S. Adults Diagnosed Diabetes by State
Figure 2.7: Number of Deaths from Diabetes by Age in the U.S.
Figure 2.8: Number of Diabetes Deaths by Race and Sex in the U.S.
Figure 2.9: Maintenance of Normal Blood Sugar Levels
Figure 2.10: Age-Adjusted Percentage of People with Diabetes Aged 35 Years or Older Reporting Heart Disease or Stroke, by Sex, in the U.S.
Figure 2.11: Percentage of Adults with Diagnosed Diabetes Reporting Any Mobility Limitation, by Age, United States
Figure 2.12: Number (in Millions) of Adults Aged 18 Years or Older with Diagnosed Diabetes Reporting Visual Impairment, United States
Figure 2.13: Mean Diabetes Healthcare-related Expenditures Per Adult (20-79 Years) with Diabetes (USD)
Figure 2.14: How Diabetes Dollars are Spent in the U.S.
Figure 2.15: Percent of Medical Condition-specific Expenditures Associated with Diabetes
Figure 3.1: Global Unit Sales of Glucose Testing Reagent Strips
Figure 3.2: Geographic Segments of the Worldwide Glucose Self-testing Market, 2013 and 2019
Figure 3.3: Worldwide Glucose Self-Testing Market by Region
Figure 4.1: Approach to Management of Hypoglycemia
Figure 4.2: Glycemic Status—Ranges and Health Implications
Figure 5.1: EGA Zones of Clinical Accuracy
Figure 5.2: Single-Day Continuous Blood Glucose Data
Figure 5.3: Factors that May Adversely Affect Glucose Testing
Figure 5.4: Personal Lancet Unit Sales Market Share by Geographic Region
Figure 6.1: Medtronic’s Threshold Suspend Feature

Index Of Tables
Table 2.1: Regional Estimates of the Number of Diabetes (20-79 Years) in Millions
Table 2.2: Countries with the Largest Numbers of Diabetics
Table 2.3: Countries with the Largest Estimated Numbers of Diabetics
Table 2.4: Worldwide Undiagnosed Diabetes in Adults (20-79 Years) by Region and Income Group
Table 2.5: Countries with the Largest Number of Deaths Attributable to Diabetes
Table 2.6: U.S. Population of Diagnosed Diabetics Aged 20 - 79 Years
Table 2.7: Percentage of U.S. Adults with Diagnosed Diabetes by State
Table 2.8: Ten Leading Diagnoses for Co-Morbid Chronic Diseases in the U.S.
Table 2.9: Odds Ratio of Progression to Complications Associated with Type 2 Diabetes
Table 2.10: Prevalence of Complications Among Patients with Diabetes
Table 2.11: Major Causes of End-stage Renal Disease
Table 2.12: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus
Table 2.13: Clinical Recommendations for Adults with Diabetes
Table 2.14: Laboratory Assessment of Diabetic Vascular Disease
Table 2.15: Average Years Gained Free of Diabetes-related Disease with Intensive Management
Table 2.16: Estimated Direct and Indirect Costs of Major Cardiovascular Diseases and Stroke in the U.S.
Table 2.17: Cost of Diagnosed Diabetes in the U.S.
Table 2.18: Annual Cost of Care of United Healthcare Adult Members with Diabetes
Table 2.19: Healthcare Utilization by Diabetic Patients
Table 3.1: Worldwide Comprehensive Glucose Testing Market (includes reagents and supplies in both the Self-testing and Professional Markets in $ Billions), 2013-2019
Table 3.2: Total Global Unit Demand for Glucose Testing Reagent Strips
Table 3.3: Global Dollar Sales of Glucose Testing Reagent Strips
Table 3.4: Worldwide Glucose Self-Testing Market Sales (Meters, Strips, and Lancets)
Table 3.5: World Market Share of Glucose Self-testing Marketers
Table 3.6: Global Revenues for Total Professional Blood Glucose Monitoring (Central Laboratory Testing and Hospital POC & POL)
Table 3.7: Global Revenues for Professional Point-of-Care Blood Glucose Monitoring Systems (within Hospitals and Physician's Offices)
Table 3.8: Global Revenues for Continuous Glucose Monitoring Systems
Table 3.9: Comprehensive Glucose Testing Market in the U.S. (includes reagents and supplies in the Self-testing and Professional Markets)
Table 3.10: U.S. Blood Glucose Reagent Strip Market (includes both Self-testing and Professional Markets)
Table 3.11: Market for Glucose Self-testing in the U.S. (includes Meters, Strips, and Lancets)
Table 3.12: Market Share of U.S. Blood Glucose Self-Testing
Table 3.13: U.S. OTC Glucose Self-Testing Market Repeat Retail Replacement Sales Percentages
Table 3.14: OTC Blood Glucose Instrument Reagents by Manufacturer Retail
Table 3.15: Demographic Characteristics Glucose Self-Testing Kit Buyers
Table 3.16: Top Brand Preferences for Glucose Self-Testing Kits
Table 3.17: Instances when Patients Prefer Professional’s Glucose Testing
Table 3.18: Advantages of a Glucose Self-Testing Kit
Table 3.19: Disadvantages of Using a Glucose Self-Testing Kit
Table 3.20: Popular Shopping Destinations for Buying or Seeking Information on Glucose Self-Testing Kits
Table 3.22: Market for Total Professional Glucose Testing (Central Laboratory and Hospital POC & POL) in the U.S., 2013-2019
Table 3.23: U.S. Revenues for Professional POC Blood Glucose Monitoring (Hospital & POL)
Table 3.24: European Comprehensive Glucose Testing Market (includes reagents and supplies in the Self-testing and Professional Markets)
Table 3.25: European Market for Glucose Self-Testing (includes Meters, Strips, and Lancets)
Table 3.26: Asian Comprehensive Glucose Testing Market (includes reagents and supplies in the Self-testing and Professional Markets)
Table 3.27: Asian Market for Glucose Self-Testing (includes Meters, Strips, and Lancets)
Table 3.28: Japanese Comprehensive Glucose Testing Market (includes reagents and supplies in the Self-testing and Professional Markets)
Table 3.29: Japanese Market for Glucose Self-Testing (includes Meters, Strips, and Lancets)
Table 3.30: Chinese Comprehensive Glucose Testing Market (includes reagents and supplies in the Self-testing and Professional Markets)
Table 3.31: Chinese Market for Glucose Self-Testing (includes Meters, Strips, and Lancets)
Table 3.32: Indian Comprehensive Glucose Testing Market (includes reagents and supplies in the Self-testing and Professional Markets)
Table 3.33: Indian Market for Glucose Self-Testing (includes Meters, Strips, and Lancets)
Table 3.34: Southeast Asian Comprehensive Glucose Testing Market (includes reagents and supplies in the Self-testing and Professional Markets)
Table 3.35: Southeast Asian Market for Glucose Self-Testing (includes Meters, Strips, and Lancets)
Table 3.36: Southeast Asian Comprehensive Glucose Testing Market by Country
Table 3.37: Southeast Asian Market for Glucose Self-Testing by Country (includes Meters, Strips, and Lancets)
Table 3.38: ROW Comprehensive Glucose Testing Market (includes reagents and supplies in the Self-testing and Professional Markets)
Table 3.39: ROW Market for Glucose Self-Testing (includes Meters, Strips, and Lancets) Professional POC
Table 3.40: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats of the Glucose Point-of-Care Market
Table 3.41: Key Market Drivers for Glucose Testing
Table 3.42: Market Drivers for Continuous Glucose Monitoring
Table 3.43: Point-of-Care Glucose Testing Market: Market Drivers Ranked in Order of Impact
Table 3.44: Key Market Restraints for Glucose Testing
Table 3.45: Market Restraints for Continuous Glucose Monitoring
Table 3.46: Point-of-Care Glucose Testing Market: Market Restraints Ranked in Order of Impact
Table 4.1: Criteria for the Diagnosis of Diabetes
Table 4.2: Categories of Increased Risk for Diabetes (Pre-Diabetes)
Table 4.3: Normal Glucose Values—Fasting State
Table 4.4: Criteria for Testing for Diabetes in Asymptomatic Adults
Table 4.5: Criteria for Type 2 Diabetes in Asymptomatic Children
Table 4.6: Screening for and Diagnosis of Gestational Diabetes Mellitus (GDM)
Table 4.7: Glycemic Recommendations for Non-Pregnant Adults with Diabetes
Table 4.8: Glycemic Recommendations for Women with Gestational Diabetes
Table 4.9: Glycemic Recommendations for Pregnant Women with Pre-existing Diabetes
Table 4.10: Plasma Blood Glucose and A1c Goals for Type 1 Diabetes by Age-group
Table 4.11: Glucose Monitoring Recommendations
Table 4.12: Key Issues for SMBG in Insulin-independent Type 2 Diabetics
Table 4.13: A1c Testing Recommendations
Table 4.14: Correlation of A1c with Mean Blood Glucose
Table 5.1: Analytic Performance Criteria for Glucose Meters
Table 5.2: Potential Variables Affecting Glucose Concentrations
Table 5.3: Key Features Considered for Glucose Testing Devices
Table 5.4: Common User Errors Made While Self-Testing for Blood Glucose
Table 5.5: Compatibility of Various Blood Glucose Meters with Icodextrin Peritoneal Dialysis (PD) Solution
Table 5.6: Ten Factors Needed to Improve the Performance of Blood Glucose Meters
Table 5.7: Features Required For Safe and Effective Meters for Hospital Settings
Table 5.8: Key Features Considered for Reagent Test Strips
Table 5.9: Differences between Laboratory Instruments for Glucose Analysis and Hand-Held Blood Glucose Meters
Table 5.10: Relationship of A1c to Average Whole Blood and Plasma Glucose Levels
Table 5.11: Unit Sales of Homecare Lancets in the U.S.
Table 5.12: Dollar Sales of Homecare Lancets in the U.S.
Table 5.13: Dollar Sales of Homecare Lancets in the E.U.
Table 5.14: Unit Sales of Homecare Glucose Self-Testing Lancets in the U.S.
Table 5.15: Unit Sales of Homecare Glucose Self-Testing Lancets in the E.U.
Table 5.16: Competition in the Lancet Market Segment
Table 5.17: Limitations of Urine Glucose Monitoring
Table 5.18: Advantages of Urine Glucose Monitoring
Table 5.19: Blood Ketone Reading Indications
Table 6.1: Current Blood Glucose Self-Testing Meters: Sample Size, Test Time, and Other Features
Table 6.2: Point of Care Blood Glucose or Blood Gas Meters Marketed for Professional Use
Table 6.3: Clinical Blood Chemistry Analyzers with Glucose Assays
Table 6.4: Detailed Features of Selected CGM Systems Currently Available
Table 6.5: Non-Invasive Glucose Monitoring Systems in Development
Table 6.6: POC Procedural Advantages for Hospital Testing
Table 6.7: Financial Comparison for Moderate and Waived CLIA Labs
Table 6.8: Data Entry and Data Management Features to Include in Future Meters
Table 6.9: Leading Companies for Patient Monitoring Products
Table 6.10: Customized Reports Must Support CAP and JCAHO Requirements

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Blood Glucose Testing and Diabetes Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/348163/">http://www.researchandmarkets.com/reports/348163/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SC2G45I6</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 10 Users:</td>
<td>USD 8000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 12000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td>__________________________________________</td>
</tr>
<tr>
<td>Last Name:</td>
<td>__________________________________________</td>
</tr>
<tr>
<td>Email Address: *</td>
<td>__________________________________________</td>
</tr>
<tr>
<td>Job Title:</td>
<td>__________________________________________</td>
</tr>
<tr>
<td>Organisation:</td>
<td>__________________________________________</td>
</tr>
<tr>
<td>Address:</td>
<td>__________________________________________</td>
</tr>
<tr>
<td>City:</td>
<td>__________________________________________</td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>__________________________________________</td>
</tr>
<tr>
<td>Country:</td>
<td>__________________________________________</td>
</tr>
<tr>
<td>Phone Number:</td>
<td>__________________________________________</td>
</tr>
<tr>
<td>Fax Number:</td>
<td>__________________________________________</td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World